AAM Statement on President Biden’s Supply Chain Executive Order | Association for Accessible Medicines
ICYMI - View memorable moments and quotes from #Access2021

AAM Statement on President Biden’s Supply Chain Executive Order

WASHINGTON, DC (February 25, 2021) — The Association for Accessible Medicines strongly supports President Biden’s America’s Supply Chains Executive Order as an important step toward strengthening the U.S. pharmaceutical supply chain and improving patient access to lower-cost generic and biosimilar medicines. The Executive Order is a prudent, considered approach to fully understanding the scope and capacity of current U.S. pharmaceutical manufacturing, while identifying specific vulnerabilities that can be targeted for resolution both immediately with the COVID-19 pandemic and longer-term as the country prepares for future public health challenges.

The U.S. government plays a critical role in encouraging the conditions that support domestic manufacturing of essential medicines. AAM believes that additional incentives, such as those included in our Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain, will be necessary as the U.S. seeks to increase its role in the global pharmaceutical supply chain.

AAM member companies, who currently employ approximately 52,000 American workers manufacturing more than 60 billion generic doses annually at 149 facilities across the country, believe that with the right incentives in place, even more American workers can contribute to a secure U.S. supply chain.

For more information about AAM and our solutions, visit www.secureourmeds.org.


Rachel Schwartz


About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending. 

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.